AUTOLOGOUS VS ALLOGENEIC
TRANSPLANT
Two different treatments sharing a name. Autologous enables chemotherapy dose escalation. Allogeneic adds immune system replacement with sustained GVL surveillance. The price of GVL is GVHD.
analyticsAt a Glance
- check_circleAutologous transplant uses the patient's own stem cells โ lower rejection risk
- check_circleAllogeneic transplant uses a matched donor โ higher curative potential but more side effects
- check_circleDisease type, stage, and patient fitness determine which approach is appropriate
- check_circleBoth types are available at specialist centres in India, China, and internationally
What This Means for Patients
Autologous: consolidates remissions, allows dose escalation beyond marrow tolerance. Standard for myeloma, lymphoma consolidation. No GVL, no GVHD. TRM 1-3%. Allogeneic: replaces hematopoietic system with donor immune system. GVL effect provides anti-tumour surveillance. GVHD risk: acute (skin, gut,
Key Insights
Understanding this topic is essential for informed transplant decisions and productive conversations with the transplant team.
Clinical Relevance
Directly impacts transplant planning, donor selection, conditioning decisions, and understanding of what the procedure accomplishes for your specific disease.
For Patients and Families
Knowledge enables better-informed questions, realistic expectations, and active participation in transplant decisions alongside the clinical team.
Benefits and Limitations
Benefits
- Allogeneic HSCT provides documented cures for specific haematologic malignancies
- Haploidentical and RIC approaches expanded the eligible patient population
- Decades of randomised trial data support disease-specific transplant indications
Limitations
- Treatment-related mortality is a real risk requiring specialist centre expertise
- GVHD remains a significant complication of allogeneic transplant
- Full recovery timeline is longer than most patients initially expect
Frequently Asked Questions
About This Topic
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Evaluating Stem Cell Transplant Options?
CancerFax connects patients with specialist transplant centres, donor matching, and comprehensive evaluation for haematologic malignancies and bone marrow failure conditions.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.